Myung Yoo, MD
Pain Medicine · Duluth, GANPI 1518120955
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,475 of the $9,327 with a category attached, or 80.1%. 31 manufacturers reported payments, led by Medtronic at 31.4% of the total. Reporting peaked in 2023 at $3,028 and has fallen 71.6% since, to $859 in 2025.
Across 312 payments — averaging $29.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Abbott$1K
- AbbVie$948
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$925
- IBSA Pharma Inc.$613
- Merz North America, Inc.$335
- plus $2K from 25 others
What the payments were for
- Travel & lodging$1,72318%
- Food & beverage$7,47580%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 33 | $2,931 |
| Abbott | 22 | $1,448 |
| AbbVie(2 entities) | 44 | $948 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 60 | $925 |
| IBSA Pharma Inc. | 46 | $613 |
| Merz North America, Inc. | 7 | $335 |
| Scilex Pharmaceuticals Inc. | 16 | $334 |
| Nevro Corp. | 5 | $287 |
| Pfizer | 16 | $239 |
| Collegium Pharmaceutical, Inc. | 11 | $232 |
| USWM, LLC | 8 | $172 |
| Ferring Pharmaceuticals Inc. | 5 | $113 |
| Kowa Pharmaceuticals America, Inc. | 6 | $98 |
| MDD US Operations, LLC | 5 | $88 |
| Hikma Pharmaceuticals USA | 5 | $81 |
| Saluda Medical Americas, Inc. | 3 | $77 |
| Azurity Pharmaceuticals, Inc. | 3 | $56 |
| Bioventus LLC | 2 | $52 |
| Arbor Pharmaceuticals, Inc. | 3 | $50 |
| Vertos Medical, Inc. | 1 | $34 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $27 |
| Kaleo, Inc. | 1 | $26 |
| Merz Pharmaceuticals, LLC | 1 | $26 |
| Masimo Corporation | 1 | $25 |
| Pacira Therapeutics, Inc. | 1 | $22 |
| Averitas Pharma Inc. | 1 | $18 |
| Redhill Biopharma Inc. | 1 | $17 |
| Valinor Pharma, LLC | 1 | $16 |
| Fidia Pharma USA Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $12 |
| Amgen | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTELLIS ADAPTIVESTIM$2,182
- PROCLAIM$513
- XEOMIN$247
- UBRELVY$226
- Omnia$145
- Proclaim IPG$128
- EUCRISA$112
- LUCEMYRA$103
- RELISTOR$103
How this compares
$9,327 in reported general payments places this provider in the 85th percentile of 203 pain medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 1,044 | $50,646 |
| PercocetOxycodone Hcl/Acetaminophen | 13 | $33,990 |
| Xtampza ErOxycodone Myristate | 69 | $26,106 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 588 | $18,068 |
| OxycontinOxycodone Hcl | 45 | $10,270 |
| Oxycodone Hcl | 530 | $8,460 |
| RoxicodoneOxycodone Hcl | 11 | $6,588 |
| LinzessLinaclotide | 12 | $6,532 |
| Morphine Sulfate ErMorphine Sulfate | 291 | $5,210 |
| Fentanyl | 35 | $2,941 |
| Morphine Sulfate | 63 | $1,833 |
| Gabapentin | 141 | $1,481 |
| Diclofenac Sodium | 36 | $1,162 |
| Pregabalin | 65 | $1,041 |
| Baclofen | 50 | $482 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $232 | $26,10669 claims |
| AbbVieLinzess | $948 | $6,53212 claims |
| Hikma Pharmaceuticals USAMorphine Sulfate | $81 | $1,83363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 203 pain medicine providers in Georgia.
Other pain medicine in Duluth
- Galal GargodhiDuluth$11K
- Rutvij ShahColumbus$86K
- Siddardth UmapathyFort Eisenhower$41K
- Susheel DuaAtlanta$36K
- Subodh AgrawalAthens$34K
- Jose MathewLawrenceville$27K
- Zhuo SunAugusta$26K
- Maged HamzaGainesville$24K
- Ankur PatelGainesville$21K
- Margaret RisoGainesville$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.